Family · Pharmaceutical analytical standards
Afatinib
A targeted cancer medicine that blocks receptors of the ErbB family (EGFR, HER2 and HER4), approved in the United States in 2013 for non-small cell lung cancer with EGFR mutations. This family brings together the active ingredient, labelled standards, nitrosamines and other impurities.
Did you know?Unlike first-generation inhibitors, which bind reversibly, it forms a covalent bond with a cysteine residue of the receptor and switches it off permanently.
No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.
